Africa Malaria Treatment Market is expected to grow with a CAGR of 6.4% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below:
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/africa-malaria-treatment-market
The Africa malaria treatment market is highly consolidated. The market has witnessed increased strategic developments owing to favorable market scenarios.
The major players dealing in the Africa malaria treatment market are introducing a strong range of product portfolios. This helped companies to maximize sales with an enhanced product portfolio.
For instance,
- In March 2020, Novartis AG donated doses of antimalarial drug hydroxychloroquine to treat several million patients fighting against the coronavirus. As hydroxychloroquine, an antimalarial drug utilized in the treatment of COVID-19, it is expected that this donation is anticipated to accelerate the market position of the company
Novartis AG is the dominating player in the Africa malaria treatment market. The other key players existing in the market include Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Cipla Inc., GlaxoSmithKline plc., Bliss GVS Pharma Ltd., MMV, Taj Pharmaceuticals Limited, Lupin Pharmaceuticals, Inc. (A Subsidiary of Lupin Limited), AJANTA PHARMA, Strides Pharma Science Limited, sanofi-aventis U.S. LLC (A Subsidiary of Sanofi), Viatris Inc., among others.
Novartis AG
Novartis AG was founded in 1996 and is headquartered in Basel, Switzerland. It has public ownership. The company focuses on innovating new solutions for various health care challenges. The company has various business segments such as Innovative Medicines and Sandoz. Under which the market-focused segment is Innovative Medicines. The company offers a range of product categories, including Afinitor Disperz/Votubia, Afinitor/Votubia, Aimovig, Arzerra, Beovu, Cibacen, Ciprodex, Comtan, Cosentyx, Diovan, KAF156, Riamet, among others in which the market-focused categories fall under KAF156, Riamet. The company is taking strategic initiatives to increase its portfolio.
- In August 2017, Novartis and Medicines for Malaria Venture (MMV) declared a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial tested the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine
The company has a global presence in the Americas, Asia-Pacific, Europe/Middle East, Africa. The company has many subsidiaries such as Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW (Australia), Novartis Austria GmbH, Vienna (Austria), Novartis Pharma NV, Vilvoorde (Belgium), Sandoz (China) Pharmaceutical (China) among others.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom. It has public ownership. The company is a leading supplier of branded generics and in-licensed products. It has business segments such as Injectables, Generics, Branded, under which the market-focused segment is Injectables. The company offers product categories including US Products, Europe Products, MENA Products, in which the market-focused category falls under US Products. The company is increasing its product portfolio such as:
- In May 2019, Hikma Pharmaceuticals PLC (Hikma) announced that it served as a Gold Sponsor of the Massachusetts Institute of Technology’s Grand Hack, which took place (May 3-5, 2019) in Cambridge Massachusetts. The Grand Hack is MIT Hacking Medicine’s annual flagship event dedicated to energize, infect and teach healthcare entrepreneurship and digital strategies to scale medicine as a way to solve health problems worldwide. It has helped the company to expand its business and make the product profile strong
The company has a global presence in Asia-Pacific, Europe, Middle East, North Africa, the U.S. The company has many subsidiaries such as Promopharm (Africa), Bedford Laboratories (London), Arab Pharmaceutical Manufacturing (Amman), Hikma Finance USA LLC (U.S.), Eurohealth (U.S.), Inc., among others.
Cipla Inc.
Cipla Inc. was founded in 1935 and is headquartered in Bombay Central, India. It has public ownership. The company is focused on ensuring access to high-quality and affordable medicines to support patients in need. Pharmaceuticals and New Ventures are some of the company's business segments under which Pharmaceuticals is the market-focused segment. The company offers a range of product categories, Our Therapies, Cipla Generics, API, in which the market-focused category falls under API. The company is taking strategic initiatives to increase its product portfolio.
- In July 2017, Cipla’s Rectal Artesunate Suppositories product contained 100 mg of Artesunate and was indicated in children from 6 months to 6 years. It was developed with the support of MMV
The company has a global presence in Australia, the U.S., Europe, Sri Lanka, South Africa, Uganda, Kenya. The company has many subsidiaries such as Cipla Medpro South Africa (Africa), Cipla USA Inc. (U.S), Breathe free lanka (pvt) ltd (Sri Lanka), Cipla canada inc (Canada), Cipla Singapore Pte Limited (Singapore), among others.
